Medico Intercontinental Limited

ICLF

INE858Q01019

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:54 2024-05-31 EDT			5-day change	1st Jan Change
45.52 ^INR	+0.22%		-1.49%	-51.02%

05-25	Medico Intercontinental Limited Reports Earnings Results for the Full Year Ended March 31, 2024	CI
05-25	Medico Intercontinental Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	CI

Medico Intercontinental Limited Reports Earnings Results for the First Quarter Ended June 30, 2021

August 14, 2021 at 05:10 am

Medico Intercontinental Limited announced earnings results for the first quarter ended June 30, 2021. For the first quarter, the company announced total revenue was INR 235.646 million compared to INR 199.928 million a year ago. Net income was INR 7.4 million compared to INR 6.653 million a year ago. Basic earnings per share was INR 2.28 compared to INR 2.05 a year ago.

Latest news about Medico Intercontinental Limited

Medico Intercontinental Limited Reports Earnings Results for the Full Year Ended March 31, 2024	05-25	CI
Medico Intercontinental Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	05-25	CI
Medico Intercontinental Limited Announces Resignation of Nikul Dipakbhai Shah as Independent Director	04-25	CI
Medico Intercontinental Limited Proposes to Incorporate Joint Venture Partnership Firm	04-09	CI
Medico Intercontinental Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-14	CI
Medico Intercontinental Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-08	CI
Medico Intercontinental Limited Approves Final Equity Dividend for the Financial Year 2022-23	23-06-30	CI
Medico Intercontinental Limited Approves the Regularisation of Priyank Lalitbhai Sancheti as an Independent Director	23-06-30	CI
Medico Intercontinental Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-06-06	CI
Medico Intercontinental Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	23-05-29	CI
Medico Intercontinental Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023, Payable on or After July 5, 2023	23-05-29	CI
Medico Intercontinental Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-14	CI
Medico Intercontinental Limited Appoints Priyank L Sancheti as an Additional Independent Director	22-11-14	CI
Medico Intercontinental Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-14	CI
Medico Intercontinental Limited Approves Regularisation of Nikul Dipakbhai Shah as an Independent Director	22-09-28	CI
Medico Intercontinental Limited announced that it expects to receive INR 249.787 million in funding	22-08-26	CI
Medico Intercontinental Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-13	CI
Medico Intercontinental Limited Announces Resignation Mr. Hiren Ravindrabhai Shah as Independent Director	22-03-30	CI
Medico Intercontinental Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-14	CI
Medico Intercontinental Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	21-11-12	CI
Medico Intercontinental Limited Reports Earnings Results for the First Quarter Ended June 30, 2021	21-08-14	CI
Medico Intercontinental Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	21-06-29	CI
Medico Intercontinental Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020	21-02-12	CI
Medico Intercontinental Limited Reports Earnings Results for the Second Quarter Ended September 30, 2020	20-11-14	CI
Medico Intercontinental Limited Reports Earnings Results for the First Quarter Ended June 30, 2020	20-09-15	CI

Chart Medico Intercontinental Limited

Duration

Period

More charts

Company Profile

Medico Intercontinental Ltd is engaged in the business of trading of pharmaceutical products. It provides platform to all research-based biopharmaceutical companies. Its product categories include gastro, uro, nutrition, cosmetology, health devices, hospital, and other areas. Its products include ACIFACT-BLI, ACIFACT-P, ACIFACT-SP (ALU-ALU), ALBECTIN, ALFACARE - D3, ARSUFACT Combokit, BALOFACT, CYCLOFACT 400, UDIFACT 150, XOFACT - 4, ZIFT SL - 250, ZYMIX, ARGIFACT, CLIANCIACT POWDER, RELIEVE CZ, VOLIREX SPRAY, RACIMAX SACHET, PERMACT, OROFACT, KTZ, FEMYACT, LIVOFACT, ZYMIX SY, ULTRATONE SY, ALBECTIN SUS, BECOFACT DROPS, MEFACT P SUS, ONCARE SOLUTION, OFCARE-FORTE SUS, PRODOM CV SY., RELIBEN SUSP., ZIFT SUSP.-200 MGCIPACT EYE DROP, OROFACT-PASTE(lamy), OROFACT MOUTH ULCER GEL, CALAMED LOTION and others. Its subsidiaries include Evagrace Pharma Private Limited, Ritz Formulations Private Limited, Sungrace Pharma Private Limited, and Azillian Healthcare Private Limited.

Sector

Pharmaceuticals

Calendar

2024-08-11 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
MEDICO INTERCONTINENTAL LIMITED	-51.02%	5.45M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+15.91%	41.97B
OTSUKA HOLDINGS CO., LTD.	+22.40%	22.34B
SANDOZ GROUP AG	+18.48%	15.25B
CIPLA LIMITED	+16.12%	14B
ZYDUS LIFESCIENCES LIMITED	+45.12%	12.06B
ONO PHARMACEUTICAL CO., LTD.	-9.58%	6.8B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.18%	5.49B